236 related articles for article (PubMed ID: 21740366)
1. Mining the adenovirus "virome" for systemic oncolytics.
Barry MA; Weaver EA; Chen CY
Curr Pharm Biotechnol; 2012 Jul; 13(9):1804-8. PubMed ID: 21740366
[TBL] [Abstract][Full Text] [Related]
2. Infection and killing of multiple myeloma by adenoviruses.
Senac JS; Doronin K; Russell SJ; Jelinek DF; Greipp PR; Barry MA
Hum Gene Ther; 2010 Feb; 21(2):179-90. PubMed ID: 19788385
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in oncolytic adenovirus therapies for cancer.
Rosewell Shaw A; Suzuki M
Curr Opin Virol; 2016 Dec; 21():9-15. PubMed ID: 27379906
[TBL] [Abstract][Full Text] [Related]
4. A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.
Wang Z; Yu B; Wang B; Yan J; Feng X; Wang Z; Wang L; Zhang H; Wu H; Wu J; Kong W; Yu X
Oncotarget; 2016 Jul; 7(30):47287-47301. PubMed ID: 27323824
[TBL] [Abstract][Full Text] [Related]
5. Mining the adenovirus virome for oncolytics against multiple solid tumor types.
Chen CY; Weaver EA; Khare R; May SM; Barry MA
Cancer Gene Ther; 2011 Oct; 18(10):744-50. PubMed ID: 21886190
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Adenoviruses for Cancer Therapy.
Tripodi L; Vitale M; Cerullo V; Pastore L
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33802281
[TBL] [Abstract][Full Text] [Related]
7. Cancer gene therapy with oncolytic adenoviruses.
Guse K; Hemminki A
J BUON; 2009 Sep; 14 Suppl 1():S7-15. PubMed ID: 19785073
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.
Ganesh S; Gonzalez-Edick M; Gibbons D; Waugh J; Van Roey M; Jooss K
Hum Gene Ther; 2009 Oct; 20(10):1201-13. PubMed ID: 19572803
[TBL] [Abstract][Full Text] [Related]
9. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
10. Chapter four--Design of improved oncolytic adenoviruses.
Alemany R
Adv Cancer Res; 2012; 115():93-114. PubMed ID: 23021243
[TBL] [Abstract][Full Text] [Related]
11. Anatomical and physical barriers to tumor targeting with oncolytic adenoviruses in vivo.
Strauss R; Lieber A
Curr Opin Mol Ther; 2009 Oct; 11(5):513-22. PubMed ID: 19806499
[TBL] [Abstract][Full Text] [Related]
12. Current issues and future directions of oncolytic adenoviruses.
Yamamoto M; Curiel DT
Mol Ther; 2010 Feb; 18(2):243-50. PubMed ID: 19935777
[TBL] [Abstract][Full Text] [Related]
13. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
[TBL] [Abstract][Full Text] [Related]
14. Species D adenoviruses as oncolytics against B-cell cancers.
Chen CY; Senac JS; Weaver EA; May SM; Jelinek DF; Greipp P; Witzig T; Barry MA
Clin Cancer Res; 2011 Nov; 17(21):6712-22. PubMed ID: 21890454
[TBL] [Abstract][Full Text] [Related]
15. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.
Uusi-Kerttula H; Hulin-Curtis S; Davies J; Parker AL
Viruses; 2015 Nov; 7(11):6009-42. PubMed ID: 26610547
[TBL] [Abstract][Full Text] [Related]
17. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.
Coughlan L; Vallath S; Gros A; Giménez-Alejandre M; Van Rooijen N; Thomas GJ; Baker AH; Cascalló M; Alemany R; Hart IR
Hum Gene Ther; 2012 Sep; 23(9):960-79. PubMed ID: 22708837
[TBL] [Abstract][Full Text] [Related]
18. Going viral: a review of replication-selective oncolytic adenoviruses.
Larson C; Oronsky B; Scicinski J; Fanger GR; Stirn M; Oronsky A; Reid TR
Oncotarget; 2015 Aug; 6(24):19976-89. PubMed ID: 26280277
[TBL] [Abstract][Full Text] [Related]
19. Strategy of Cancer Targeting Gene-Viro-Therapy (CTGVT) a trend in both cancer gene therapy and cancer virotherapy.
Liu XY; Li HG; Zhang KJ; Gu JF
Curr Pharm Biotechnol; 2012 Jul; 13(9):1761-7. PubMed ID: 21740358
[TBL] [Abstract][Full Text] [Related]
20. [Oncolytic adenoviruses in anti-cancer therapy: current status and perspectives].
Sviatchenko VA; Tarasova MV; Netesov SV; Chumakov PM
Mol Biol (Mosk); 2012; 46(4):556-69. PubMed ID: 23113343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
